These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 9285659)
21. Quality of life variables in the selection of rate versus rhythm control in patients with atrial fibrillation: observations from the Canadian Trial of Atrial Fibrillation. Dorian P; Mangat I Card Electrophysiol Rev; 2003 Sep; 7(3):276-9. PubMed ID: 14739727 [TBL] [Abstract][Full Text] [Related]
22. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management. Gillis AM; Verma A; Talajic M; Nattel S; Dorian P; Can J Cardiol; 2011; 27(1):47-59. PubMed ID: 21329862 [TBL] [Abstract][Full Text] [Related]
23. Dronedarone: a promising alternative for the management of atrial fibrillation. Yalta K; Turgut OO; Yilmaz MB; Yilmaz A; Tandogan I Cardiovasc Drugs Ther; 2009 Oct; 23(5):385-93. PubMed ID: 19669399 [TBL] [Abstract][Full Text] [Related]
26. Dronedarone for the treatment of atrial fibrillation and atrial flutter. Maund E; McKenna C; Sarowar M; Fox D; Stevenson M; Pepper C; Palmer S; Woolacott N Health Technol Assess; 2010 Oct; 14(Suppl. 2):55-62. PubMed ID: 21047492 [TBL] [Abstract][Full Text] [Related]
27. Pharmacological management of atrial fibrillation: an update. Hohnloser SH; Li YG; Bender B; Grönefeld G J Cardiovasc Pharmacol Ther; 2000 Jan; 5(1):11-6. PubMed ID: 10687669 [TBL] [Abstract][Full Text] [Related]
28. [Treatment of atrial fibrillation in a Hungarian hospital department of cardiologic internal medicine at the turn of the millennium]. Márk L; Erdej F; Dani G; Borbély M; Sziklai G; Nagy E; Hajdara I; Katona A Orv Hetil; 2004 May; 145(19):1001-6. PubMed ID: 15181735 [TBL] [Abstract][Full Text] [Related]
29. Limitations to antiarrhythmic drug use in patients with atrial fibrillation. Humphries KH; Kerr CR; Steinbuch M; Dorian P; CMAJ; 2004 Sep; 171(7):741-5. PubMed ID: 15451836 [TBL] [Abstract][Full Text] [Related]
30. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial. Gulizia M; Mangiameli S; Orazi S; Chiarandà G; Piccione G; Di Giovanni N; Colletti A; Pensabene O; Lisi F; Vasquez L; Grammatico A; Boriani G; Am Heart J; 2008 Jan; 155(1):100-7, 107.e1. PubMed ID: 18082498 [TBL] [Abstract][Full Text] [Related]
31. A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned. Vijayalakshmi K; Whittaker VJ; Sutton A; Campbell P; Wright RA; Hall JA; Harcombe AA; Linker NJ; Stewart MJ; Davies A; de Belder MA Am Heart J; 2006 Apr; 151(4):863.e1-6. PubMed ID: 16569550 [TBL] [Abstract][Full Text] [Related]
32. Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial. Wong CK; White HD; Wilcox RG; Criger DA; Califf RM; Topol EJ; Ohman EM Card Electrophysiol Rev; 2003 Sep; 7(3):201-7. PubMed ID: 14739713 [TBL] [Abstract][Full Text] [Related]
33. Low-dose amiodarone for atrial fibrillation: time for a prospective study? Middlekauff HR; Wiener I; Saxon LA; Stevenson WG Ann Intern Med; 1992 Jun; 116(12 Pt 1):1017-20. PubMed ID: 1586091 [TBL] [Abstract][Full Text] [Related]
34. Long-term omega-3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion. Kumar S; Sutherland F; Morton JB; Lee G; Morgan J; Wong J; Eccleston DE; Voukelatos J; Garg ML; Sparks PB Heart Rhythm; 2012 Apr; 9(4):483-91. PubMed ID: 22120130 [TBL] [Abstract][Full Text] [Related]
35. Pharmacologic management of atrial fibrillation: established and emerging options. Kalus JS J Manag Care Pharm; 2009 Aug; 15(6 Suppl B):S10-8. PubMed ID: 19678722 [TBL] [Abstract][Full Text] [Related]
36. Augmenting maintenance of sinus rhythm in the control of atrial fibrillation by antiarrhythmic drug combinations. Singh BN J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4 Suppl):31S-5S. PubMed ID: 21098417 [TBL] [Abstract][Full Text] [Related]
37. A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation. Joseph AP; Ward MR Ann Emerg Med; 2000 Jul; 36(1):1-9. PubMed ID: 10874228 [TBL] [Abstract][Full Text] [Related]
38. [Predictors of reversion to sinus rhythm previous to electrical cardioversion in patients with persistent atrial fibrillation treated with anti-arrhythmic drugs]. Viñolas X; Freire F; Romero-Menor C; Alegret JM Med Clin (Barc); 2013 Apr; 140(8):351-5. PubMed ID: 22982132 [TBL] [Abstract][Full Text] [Related]
39. Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]). Singh SN; Singh BN; Reda DJ; Fye CL; Ezekowitz MD; Fletcher RD; Sharma SC; Atwood JE; Jacobson AK; Lewis HD; Antman EM; Falk RH; Lopez B; Tang XC Am J Cardiol; 2003 Aug; 92(4):468-72. PubMed ID: 12914883 [TBL] [Abstract][Full Text] [Related]
40. Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Kochiadakis GE; Igoumenidis NE; Marketou ME; Solomou MC; Kanoupakis EM; Vardas PE Am J Cardiol; 1998 Apr; 81(8):995-8. PubMed ID: 9576159 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]